Tumor-stromal interactions in bone metastasis

Current Osteoporosis Reports

Volumn 8, Issue 2, 2010, Pages 105-113

  Nannuru, Kalyan C ^a   Singh, Rakesh K ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Bone metastasis.; Bone microenvironment; MMPs.; Tumor stromal.

Indexed keywords

1,10 PHENANTHROLINE; BISPHOSPHONIC ACID DERIVATIVE; CATHEPSIN; CELL ADHESION MOLECULE; CHELATING AGENT; CHEMOKINE; CHEMOKINE RECEPTOR; CYTOKINE; ENDOTHELIN; GROWTH FACTOR; MATRIX METALLOPROTEINASE; PROTEINASE; PROTEINASE INHIBITOR; SOMATOMEDIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA;

BONE DEFECT; BONE MARROW CELL; BONE MATRIX; BONE METASTASIS; BONE REMODELING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER PAIN; CANCER PREVENTION; CANCER SURVIVAL; CARCINOGENESIS; CELL INTERACTION; CELL KINETICS; DISTANT METASTASIS; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SYNTHESIS; HUMAN; IMMUNOCYTOCHEMISTRY; MOLECULAR DYNAMICS; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OVERALL SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR CELL; TUMOR MICROENVIRONMENT; BONE TUMOR; CELL COMMUNICATION; DISEASE COURSE; METASTASIS; OSTEOBLAST; PATHOLOGY; SECONDARY;

BONE NEOPLASMS; CELL COMMUNICATION; DISEASE PROGRESSION; HUMANS; NEOPLASM METASTASIS; OSTEOBLASTS;

EID: 77955982168     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-010-0011-6     Document Type: Review

References (55)

1. Paget S: The distribution of secondary growths in cancer of the breast. Lancet 1889, 133:571-573.
2. Fidler IJ, Kripke ML: Metastasis results from preexisting variant cells within a malignant tumor. Science 1977, 197:893-895.
3. Hart IR, Fidler IJ: Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res 1980, 40:2281-22874.
4. Fidler IJ, Poste G: The "seed and soil" hypothesis revisited.Lancet Oncol 2008, 9:808. This is an important review of the well-known "seed and soil" hypothesis in metastasis with reference to the latest understanding of metastatic determinants.
5. Suva LJ, Griffin RJ, Makhoul I: Mechanisms of bone metastases of breast cancer. Endocr Relat Cancer 2009, 16:703-713. This paper highlights the underlying mechanisms of breast cancer bone metastasis.
6. Leong SP, Cady B, Jablons DM, et al.: Clinical patterns of metastasis. Cancer Metastasis Rev 2006, 25:221-232.
7. Joyce JA, Pollard JW: Microenvironmental regulation of metastasis. Nat Rev Cancer 2009, 9:239-252. This comprehensive review highlights the role of the microenvironment in metastasis regulation.
8. Bussard KM, Gay CV, Mastro AM: The bone microenvironment in metastasis; what is special about bone? Cancer Metastasis Rev 2008, 27:41-55.
9. Mundy GR: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002, 2:584-593.
10. Lester J, Dodwell D, McCloskey E, Coleman R: The causes and treatment of bone loss associated with carcinoma of the breast. Cancer Treat Rev 2005, 31:115-142.
11. Gabbitas B, Canalis E: Growth factor regulation of insulin-like growth factor binding protein-6 expression in osteoblasts. J Cell Biochem 1997, 66:77-86.
12. Kakonen SM, Mundy GR: Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 2003, 97:834-839.
13. Birkedal-Hansen H: Catabolism and turnover of collagens: collagenases. Methods Enzymol 1987, 144:140-171.
14. Leppa S, Saarto T, Vehmanen L, et al.: A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. Clin Cancer Res 2004, 10:1057-1063.
15. Saad S, Bendall LJ, James A, et al.: Induction of matrix metalloproteinases MMP-1 and MMP-2 by co-culture of breast cancer cells and bone marrow fibroblasts. Breast Cancer Res Treat 2000, 63:105-115.
16. Zhao W, Byrne MH, Boyce BF, Krane SM: Bone resorption induced by parathyroid hormone is strikingly diminished in collagenase-resistant mutant mice. J Clin Invest 1999, 103:517-524.
17. Wilson TJ, Singh RK: Proteases as modulators of tumor-stromal interaction: primary tumors to bone metastases. Biochim Biophys Acta 2008, 1785:85-95. This is an interesting review of proteases and their role in tumor-stromal interaction.
18. Coleman RE: Risks and benefits of bisphosphonates. Br J Cancer 2008, 98:1736-1740.
19. Ohshiba T, Miyaura C, Inada M, Ito A: Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis. Br J Cancer 2003, 88:1318-1326.
20. Yoneda T, Sasaki A, Dunstan C, et al.: Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 1997, 99:2509-2517.
21. Sheng S, Carey J, Seftor EA, et al.: Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc Natl Acad Sci U S A 1996, 93:11669-11674.
22. Cher ML, Biliran Jr HR, Bhagat S, et al.: Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis. Proc Natl Acad Sci U S A 2003, 100:7847-7852.
23. Lynch CC, Hikosaka A, Acuff HB, et al.: MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 2005, 7:485-496.
24. Dong Z, Bonfil RD, Chinni S, et al.: Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue. Am J Pathol 2005, 166:1173-1186.
25. Ishibashi O, Niwa S, Kadoyama K, Inui T: MMP-9 antisense oligodeoxynucleotide exerts an inhibitory effect on osteoclastic bone resorption by suppressing cell migration. Life Sci 206, 79:1657-1660.
26. Ishikawa T, Kamiyama M, Tani-Ishii N, et al.: Inhibition of osteoclast differentiation and bone resorption by cathepsin K antisense oligonucleotides. Mol Carcinog 2001, 32:84-91.
27. Wilson TJ, Nannuru KC, Futakuchi M, et al.: Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-{kappa}B Ligand. Cancer Res 2008, 68:5803-5811.
28. Wilson TJ, Nannuru KC, Singh RK: Cathepsin G recruits osteoclast precursors via proteolytic activation of proteaseactivated receptor-1. Cancer Res 2009, 69:3188-3195.
29. Wilson TJ, Nannuru KC, Futakuchi M, Singh RK: Cathepsin Gmediated enhanced TGF-beta signaling promotes angiogenesis via upregulation of VEGF and MCP-1. Cancer Lett 2010, 288:162-169. This is an important study defining the novel role of cathepsin G in TGF-β signaling and angiogenesis.
30. Thomas RJ, Guise TA, Yin JJ, et al.: Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999, 140:4451-4458.
31. Yin JJ, Selander K, Chirgwin JM, et al.: TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999, 103:197-206.
32. Bendre MS, Margulies AG, Walser B, et al.: Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res 2005, 65:11001-11009.
33. Thiolloy S, Halpern J, Holt GE, et al.: Osteoclast-derived matrix metalloproteinase-7, but not matrix metalloproteinase-9, contributes to tumor-induced osteolysis. Cancer Res 2009, 69:6747-6755. This is an important study delineating the role of proteases in osteolytic tumor using knockout mouse models.
34. Mengshol JA, Vincenti MP, Brinckerhoff CE: IL-1 induces collagenase-3 (MMP-13) promoter activity in stably transfected chondrocytic cells: requirement for Runx-2 and activation by p38 MAPK and JNK pathways. Nucleic Acids Res 2001, 29:4361-4372.
35. Sakamoto H, Ochiya T, Sato Y, et al.: Adenovirus-mediated transfer of the HST-1 (FGF4) gene induces increased levels of platelet count in vivo. Proc Natl Acad Sci U S A 1994, 91:12368-12372.
36. Guise TA, Kozlow WM, Heras-Herzig A, et al.: Molecular mechanisms of breast cancer metastases to bone. Clin Breast Cancer 2005, 5(Suppl):S46-S53.
37. Koeneman KS, Yeung F, Chung LW: Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999, 39:246-261.
38. Wilson TJ, Nannuru KC, Singh RK: Cathepsin G-mediated activation of pro-matrix metalloproteinase 9 at the tumor-bone interface promotes transforming growth factor-beta signaling and bone destruction. Mol Cancer Res 2009, 7:1224-1233. This important study demonstrates the interplay of cathepsin G, TGF- β, and MMP-9 in tumor-induced osteolysis.
39. Massagué J: TGFbeta in cancer. Cell 2008, 34:215-230.
40. Harris SE, Bonewald LF, Harris MA, et al.: Effects of transforming growth factor beta on bone nodule formation and expression of bone morphogenetic protein 2, osteocalcin, osteopontin, alkaline phosphatase, and type I collagen mRNA in longterm cultures of fetal rat calvarial osteoblasts. J Bone Miner Res 1994, 9:855-863.
41. Futakuchi M, Nannuru KC, Varney ML, et al.: Transforming growth factor-beta signaling at the tumor-bone interface promotes mammary tumor growth and osteoclast activation. Cancer Sci 2009, 100:71-81.
42. Dunn LK, Mohammad KS, Fournier PG, et al.: Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS One 2009, 4:e6896.
43. Nemeth JA, Yousif R, Herzog M, et al.: Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J. Natl Cancer Inst 2002, 94:17-25.
44. Mitsiades CS, Mitsiades NS, McMullan CJ, et al.: Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004, 5:221-230.
45. Doerr ME, Jones JI: The roles of integrins and extracellular matrix proteins in the insulin-like growth factor I-stimulated chemotaxis of human breast cancer cells. J Biol Chem 1996, 271:2443-2447.
46. Takuwa Y, Masaki T, Yamashita K: The effects of the endothelin family peptides on cultured osteoblastic cells from rat calvariae. Biochem Biophys Res Commun 1990, 170:998-1005.
47. Guise TA, Chirgwin JM: Transforming growth factor-beta in osteolytic breast cancer bone metastases. Clin Orthop Relat Res 2003, 415(Suppl):S32-S38.
48. Chiao JW, Moonga BS, Yang YM, et al.: Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. Br J Cancer 2000, 83:360-365.
49. Singh S, Sadanandam A, Singh RK: Chemokines in tumor angiogenesis and metastasis. Cancer Metastasis Rev 2007, 26:453-467. This paper highlights the role of chemokines in tumor angiogenesis and metastasis.
50. Murphy PM: Chemokines and the molecular basis of cancer metastasis. N Engl J Med 2001, 345:833-835.
51. Muller A, Homey B, Soto H, et al.: Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
52. Nakamura ES, Koizumi K, Kobayashi M, et al.: RANKL-induced CCL22/macrophage-derived chemokine produced from osteoclasts potentially promotes the bone metastasis of lung cancer expressing its receptor CCR4. Clin Exp Metastasis 2006, 23:9-18.
53. Chinni SR, Sivalogan S, Dong Z, et al.: CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Prostate 2006, 66:32-48.
54. Takahashi M, Miyazaki H, Furihata M, et al.: Chemokine CCL2/ MCP-1 negatively regulates metastasis in a highly bone marrowmetastatic mouse breast cancer model. Clin Exp Metastasis 2009, 26:817-828.
55. Pantel K, Alix-Panabieres C, Riethdorf S: Cancer micrometastases. Nat Rev Clin Oncol 2009, 6:339-351